|
1
|
Howlader N, Forjaz G, Mooradian MJ, Meza
R, Kong CY, Cronin KA, Mariotto AB, Lowy DR and Feuer EJ: The
effect of advances in lung-cancer treatment on population
mortality. N Engl J Med. 383:640–649. 2020.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Schwartz AG and Cote ML: Epidemiology of
lung cancer. Adv Exp Med Biol. 893:21–41. 2016.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Yang F, Li H and Wang J: The precision
surgical treatment strategies of lung adenocarcinoma under the
guidance of the WHO new classification. Zhonghua Wai Ke Za Zhi.
55:49–53. 2017.PubMed/NCBI View Article : Google Scholar : (In Chinese).
|
|
4
|
Morales-Oyarvide V and Mino-Kenudson M:
Tumor islands and spread through air spaces: Distinct patterns of
invasion in lung adenocarcinoma. Pathol Int. 66:1–7.
2016.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Kometani T, Sugio K, Osoegawa A, Seto T
and Ichinose Y: Clinicopathological features of younger (aged ≤50
years) lung adenocarcinoma patients harboring the EML4-ALK fusion
gene. Thoracic Cancer. 9:563–570. 2018.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Senan S, Paul MA and Lagerwaard FJ:
Treatment of early-stage lung cancer detected by screening: Surgery
or stereotactic ablative radiotherapy? Lancet Oncol. 14:e270–e274.
2013.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Jiang N and Xu X: Exploring the survival
prognosis of lung adenocarcinoma based on the cancer genome atlas
database using artificial neural network. Medicine (Baltimore).
98(e15642)2019.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Chang CH, Lee CH and Wang JY: Gefitinib or
erlotinib for previously treated lung adenocarcinoma: Which is
superior? J Clin Oncol. 35:1374–1375. 2017.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Gustafsson A, Fritz HKM and Dahlbäck B:
Gas6-Axl signaling in presence of Sunitinib is enhanced,
diversified and sustained in renal tumor cells, resulting in
tumor-progressive advantages. Exp Cell Res. 355:47–56.
2017.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Antony J, Tan TZ, Kelly Z, Low J, Choolani
M, Recchi C, Gabra H, Thiery JP and Huang RYJ: The GAS6-AXL
signaling network is a mesenchymal (Mes) molecular subtype-specific
therapeutic target for ovarian cancer. Sci Signal.
9(ra97)2016.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Jin Y, Nie D, Li J, Du X, Lu Y, Li Y, Liu
C, Zhou J and Pan J: Gas6/AXL signaling regulates self-renewal of
chronic myelogenous leukemia stem cells by stabilizing
beta-catenin. Clin Cancer Res. 23:2842–2855. 2017.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Sawabu T, Seno H, Kawashima T, Fukuda A,
Uenoyama Y, Kawada M, Kanda N, Sekikawa A, Fukui H, Yanagita M, et
al: Growth arrest-specific gene 6 and Axl signaling enhances
gastric cancer cell survival via Akt pathway. Mol Carcinog.
46:155–164. 2007.PubMed/NCBI View
Article : Google Scholar
|
|
13
|
Lee HJ, Jeng YM, Chen YL, Chung L and Yuan
RH: Gas6/Axl pathway promotes tumor invasion through the
transcriptional activation of slug in hepatocellular carcinoma.
Carcinogenesis. 35:769–775. 2014.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Sinha S, Boysen J, Nelson M, Secreto C,
Warner SL, Bearss DJ, Lesnick C, Shanafelt TD, Kay NE and Ghosh AK:
Targeted Axl inhibition primes chronic lymphocytic leukemia B cells
to apoptosis and shows synergistic/additive effects in combination
with BTK inhibitors. Clin Cancer Res. 21:2115–2126. 2015.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Morizono K, Xie Y, Olafsen T, Lee B,
Dasgupta A, Wu AM and Chen IS: The soluble serum protein Gas6
bridges virion envelope phosphatidylserine to the TAM receptor
tyrosine kinase Axl to mediate viral entry. Cell Host Microbe.
9:286–298. 2011.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Testa U, Castelli G and Pelosi E: . Lung
cancers: Molecular characterization, clonal heterogeneity and
evolution, and cancer stem cells. Cancers (Basel).
10(248)2018.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Kariolis MS, Miao YR, Diep A, Nash SE,
Olcina MM, Jiang D, Jones DS II, Kapur S, Mathews II, Koong AC, et
al: Inhibition of the GAS6/AXL pathway augments the efficacy of
chemotherapies. J Clin Invest. 127:183–198. 2017.PubMed/NCBI View
Article : Google Scholar
|
|
19
|
Wang C, Jin H, Wang N, Fan S, Wang Y,
Zhang Y, Wei L, Tao X, Gu D, Zhao F, et al: Gas6/Axl axis
contributes to chemoresistance and metastasis in breast cancer
through Akt/GSK-3β/β-catenin signaling. Theranostics. 6:1205–1219.
2016.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Zhao CC, Chen J, Niu RF, Liu Y and Zhang
CG: Increased resistin suggests poor prognosis and promotes
development of lung adenocarcinoma. Oncol Rep. 40:3392–33404.
2018.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Faget J, Contat C, Zangger N, Peters S and
Meylan E: RANKL Signaling sustains primary tumor growth in
genetically engineered mouse models of lung adenocarcinoma. J
Thorac Oncol. 13:387–398. 2018.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Han J, Tian R, Yong B, Luo C, Tan P, Shen
J and Peng T: Gas6/Axl mediates tumor cell apoptosis, migration and
invasion and predicts the clinical outcome of osteosarcoma
patients. Biochem Biophys Res Commun. 435:493–500. 2013.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Rankin EB, Fuh KC, Taylor TE, Krieg AJ,
Musser M, Yuan J, Wei K, Kuo CJ, Longacre TA and Giaccia AJ: AXL is
an essential factor and therapeutic target for metastatic ovarian
cancer. Cancer Res. 70:7570–7579. 2010.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Sainaghi PP, Castello L, Bergamasco L,
Galletti M, Bellosta P and Avanzi GC: Gas6 induces proliferation in
prostate carcinoma cell lines expressing the Axl receptor. J Cell
Physiol. 204:36–44. 2005.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Seike M, Kim CH, Zou F, Noro R, Chiba M,
Ishikawa A, Κunugi S, Kubota K and Gemma A: AXL and GAS6
co-expression in lung adenocarcinoma as a prognostic classifier.
Oncol Rep. 37:3261–3269. 2017.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Scafoglio CR, Villegas B, Abdelhady G,
Bailey ST, Liu J, Shirali AS, Wallace WD, Magyar CE, Grogan TR,
Elashoff D, et al: Sodium-glucose transporter 2 is a diagnostic and
therapeutic target for early-stage lung adenocarcinoma. Sci Transl
Med. 10(eaat5933)2018.PubMed/NCBI View Article : Google Scholar
|
